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Abstract 
Abnormal development of the ocular anterior segment may lead to a spectrum of clinical 
phenotypes ranging from primary congenital glaucoma (PCG) to variable anterior segment 
dysgenesis (ASD). The main objective of this study was to identify the genetic alterations 
underlying recessive congenital glaucoma with ASD (CG-ASD). Next-generation DNA 
sequencing identified rare biallelic CPAMD8 variants in four patients with CG-ASD and in 
one case with PCG. CPAMD8 is a gene of unknown function and recently associated with 
ASD. Bioinformatic and in vitro functional evaluation of the variants using quantitative 
reverse transcription PCR and minigene analysis supported a loss-of-function pathogenic 
mechanism. Optical and electron microscopy of the trabeculectomy specimen from one of 
the CG-ASD cases revealed an abnormal anterior chamber angle, with altered extracellular 
matrix, and apoptotic trabecular meshwork cells. The CPAMD8 protein was 
immunodetected in adult human ocular fluids and anterior segment tissues involved in 
glaucoma and ASD (i.e., aqueous humor, non-pigmented ciliary epithelium and iris muscles), 
as well as in periocular mesenchyme-like cells of zebrafish embryos. CRISPR/Cas9 disruption 
of this gene in F0 zebrafish embryos (96 hpf) resulted in varying degrees of gross 
developmental abnormalities, including microphthalmia, pharyngeal maldevelopment, and 
pericardial and periocular edemas. Optical and electron microscopy examination of these 
embryos showed iridocorneal angle hypoplasia (characterized by altered iris stroma cells, 
reduced anterior chamber, and collagen disorganized corneal stroma extracellular matrix), 
recapitulating some patients’ features. Our data support the notion that CPAMD8 loss-of-
function underlies a spectrum of recessive CG-ASD phenotypes associated with extracellular 
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matrix disorganization and provide new insights into the normal and disease roles of this 
gene. 
Keywords 
Congenital glaucoma; anterior segment dysgenesis; CPAMD8, zebrafish. 
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Introduction 
Primary congenital glaucoma (PCG) and anterior segment dysgenesis (ASD) are related and 
heterogeneous diseases that may severely impair visual function. They result from diverse 
developmental abnormalities of the ocular anterior segment structures, which include the 
Schlemm’s canal (SC), trabecular meshwork (TM), ciliary body (CB), iris and cornea (Kupfer 
and Kaiser-Kupfer 1978, 1979). PCG is caused by a malformation restricted to the TM and/or 
SC, i.e., trabeculodysgenesis or gonyodysgenesis (Gould and John 2002), which results in 
elevated intraocular pressure (IOP) and in the classical triad of epiphora, blepharospasm 
and photophobia (Papadopoulos et al. 2013). Ocular enlargement and curvilinear breaks in 
the Descemet’s membrane (Haab striae) may also be present in some patients. Typical PCG 
is usually diagnosed in the neonatal or infantile period. On the other hand, ASD 
malformation and its associated clinical features are highly variable and may include 
underdevelopment of the iris (iris hypoplasia), altered corneal diameter, corneal opacity 
(leukoma) and vascularization, posterior embryotoxon (thickened and displaced Schwalbe's 
line), displacement of the pupil (corectopia), the existence of more than one pupillary 
opening (polycoria), an abnormal iridocorneal angle, anterior synechiae between the iris 
and posterior corneal surface, displacement of the lens (ectopia lentis), and adhesion 
between the cornea and the lens or the pupillary border (Peters’ anomaly) (Sowden 2007). 
The specific combination of posterior embryotoxon, iris hypoplasia, corectopia/polycoria, 
and/or anterior synechiae is recognized as a separate diagnostic entity called Axenfeld-
Rieger anomaly, which combines with systemic anomalies in the Axenfeld-Rieger syndrome 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
(Reis and Semina 2011). In addition, ASD is generally associated with an approximate 50% 
risk for glaucoma (Reis and Semina 2011). 
Both PCG and ASD are believed to be caused by defective patterning, migration and/or 
differentiation of periocular mesenchyme cells, which derive mainly from the neural crest 
but also from paraxial mesoderm (Creuzet et al. 2005). Moreover, PCG and ASD may be 
caused by the same genes (Gould and John 2002). In this line, mutations in CYP1B1 mainly 
produce PCG but have also been detected in some patients with Peters’ (Vincent et al. 2006; 
Vincent et al. 2001) and Rieger’s anomalies (Chavarria-Soley et al. 2006). A common feature 
of many ASD diseases is disturbance of the extracellular matrix (ECM) composition and 
abundance, although the specific underlying alterations remain mostly unidentified. ECM 
signaling has been postulated as being one relevant component of the networks involved 
in anterior segment development (Gould et al. 2004). Functional disruption of this complex 
developmental regulation may occur at different points in different patients, leading to 
genetic and clinical variability and to the overlapping phenotypic features observed in 
different ASD subtypes. This scenario presents challenges in terms of the correct diagnosis 
and classification of patients. 
Unlike other ASDs, which are frequently dominant, PCG is generally transmitted in an 
autosomal-recessive fashion, but incomplete penetrance and variable expressivity are 
present in all these dysgenesis (Sarfarazi and Stoilov 2000). The first identified and most 
prevalent cause of recessive PCG is CYP1B1 loss-of-function (LoF) (Sarfarazi and Stoilov 
2000; Stoilov et al. 1997), which is present in 18%-48% of non-consanguineous European 
patients (Campos-Mollo et al. 2009; Colomb et al. 2003; López-Garrido et al. 2013; 
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Weisschuh et al. 2009). Additional genes reported to play a role in this pathology are LTBP2 
(Ali et al. 2009), MYOC (Kaur et al. 2005), FOXC1 (Medina-Trillo et al. 2016; Medina-Trillo et 
al. 2015), TEK (Souma et al. 2016) and GPATCH3 (Ferre-Fernández et al. 2017), illustrating 
the genetic heterogeneity of this disease. 
The principal known genes that cause different types of typical dominant ASD are FOXC1 
(Nishimura et al. 1998) and PITX2 (Semina et al. 1996), which are mainly involved in 
Axenfeld-Rieger alterations. In addition, PAX6 is linked to Peters’ anomaly (Hanson et al. 
1994) and aniridia (Jordan et al. 1992). Cases of recessive ASD transmission have also been 
described (Reis and Semina 2011). Recently, in three families, rare CPAMD8 variants have 
been identified as the cause of an atypical form of autosomal recessive ASD characterized 
by bilateral iris hypoplasia, ectopia lentis, corectopia, ectropion uveae, and cataracts (ASD8, 
OMIM # 617319) (Cheong et al. 2016). 
In this study we investigate the genetic alterations underlying glaucoma with ASD (CG-ASD) 
and isolated PCG in a group of unrelated patients who have no family history of the disease 
and who have variable clinical features. We found that these patients carry rare biallelic 
CPAMD8 LoF variants associated with ECM alterations. In addition, we show that this gene 
plays a role in ocular ECM formation and in early ocular development, providing new 
insights into the molecular pathways involved in anterior segment morphogenesis and 
associated diseases. 
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Methods 
Subjects 
Patients were recruited at San Carlos Clinic Hospital and University Hospital Fundación 
Jimenez Diaz, Madrid, Spain. Four patients diagnosed with CG-ASD and 50 PCG patients 
selected from a cohort composed of 150 unrelated cases (López-Garrido et al. 2013) with 
no family history of the disease and no CYP1B1, FOXC1, FOXC2 or MYOC pathogenic variants 
were selected for genetic studies. The clinical features of this PCG cohort have previously 
been reported (Campos-Mollo et al. 2009; López-Garrido et al. 2013). Glaucoma specialists 
carried out the clinical examination of all patients, which included slit-lamp biomicroscopy, 
gonioscopy, biometry, IOP measurement, and ophthalmoscopy. PCG diagnosis was 
performed as previously described (López-Garrido et al. 2013). The human study and 
informed consent procedures were approved by the Ethics Committee for Human Research 
of the University Hospital Fundación Jiménez Díaz and Hospital Clínico San Carlos (approval 
number 13/388-E). The research followed the tenets of the Declaration of Helsinki. 
Informed written consents were obtained prior to participants’ inclusion in the study. 
Human tissue samples 
A human eye from a 45-year-old Caucasian female donor (cadaver) with no reported ocular 
pathology was obtained within 24 hours after enucleation from the USA National Disease 
Research Interchange. Tears collected from one healthy 32-year-old female volunteer, a 
member of the research group, were used for Western blot analysis. Tissue processing is 
described in the Suppl. Methods. 
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Animals 
Wild-type AB zebrafish (Danio rerio) were maintained at 28° C with a 14 h on/10 h off light 
cycle and were fed a standard diet according to established protocols (Westerfield 2000). 
Detailed embryo management protocols are available in the Suppl. Methods. All animal 
husbandry and experiments were approved and conducted in accordance with the 
guidelines set forth by the Institutional Animal Research Committee of the University of 
Castilla-La Mancha (approval number PR-2015-04-10). 
Next generation sequencing 
Genomic DNA was extracted from the subjects’ peripheral blood, using the QIAamp DNA 
Blood Mini Kit (Quiagen) and processed for targeted NGS using a custom gene panel 
composed of coding and non-coding exons and 25pb of intronic boundaries of 82 genes 
involved in glaucoma, ASD, and ocular development. The gene panel also included full 
intronic sequences and 22 putative regulatory regions of CYP1B1 and LRP2 genes. The panel 
was developed using the SureSelect QXT capture technology (Agilent Technologies). 
Detailed protocols are available in the Suppl. Methods. Bioinformatic analysis was 
performed using standard procedures and custom in-house pipelines for both SNVs analysis 
and read-count based CNVs analysis, as previously reported (Ceroni et al. 2019) and are 
described in detail in the Suppl. Methods. 
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Variant prioritization and validation 
Candidate disease-causing variants were identified through the application of a multistep 
filtering approach. Initially, common variants, defined as those with a minor allele frequency 
higher than 1% in the Exome Aggregation Consortium (ExAC) 
(http://exac.broadinstitute.org/) or gnomAD (https://gnomad.broadinstitute.org/) 
browsers and with a genotype quality lower than 50 reads were filtered out. Next, LoF 
variants (nonsense, indels producing a frameshift and variants affecting canonical splicing 
sites) were selected. If no candidate variants met the later stringent functional criterium, 
we included missense, synonymous and non-canonical splicing variants bioinformatically 
predicted to cause deleterious effects, using the software described below. Finally, to 
identify potential recessive genotypes, we selected variants in compound heterozygosis or 
homozygosis. The detailed variant filtering pipelines followed in this study are summarized 
in Fig. 1A and 3A. The DNA sample for WES was processed as previously described (Ferre-
Fernández et al. 2017). Candidate variants identified by NGS were verified and segregated 
in the corresponding families by Sanger sequencing following PCR amplification using 
conditions and primers indicated Table S1. 
CNV validation 
A CNV affecting the CPAMD8 exon 23 was validated and segregated in the family 
using copy-number quantification by droplet digital PCR (ddPCR). Detailed protocols are 
available in the Suppl. Methods. 
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Quantitative reverse transcription PCR (qRT-PCR) 
Density gradient centrifugation of peripheral whole blood using Ficoll-Paque PLUS 
(GE Healthcare Biosciences) was used to isolate mononuclear cells from CG-ASD-104 family 
members and from two healthy controls who did not carry pathogenic CPAMD8 variants. 
RNA was isolated using the RNeasy Minikit (Qiagen #74104) and treated with RNase-free 
DNase I according to the manufacturer's instructions. Purified RNA was used for cDNA 
synthesis using RevertAid First Strand cDNA Synthesis Kits (Thermo Scientific #K1622). The 
expression of CPAMD8 mRNA relative to PRLP0 mRNA was determined using the 2−ΔΔCt 
method (Livak and Schmittgen 2001). Detailed protocols are available in the Suppl. 
Methods. 
Splicing analysis 
Both wild-type and mutant exon 15 of CPAMD8 and their flanking sequences (390 
bp and 280 bp of introns 14 and 15, respectively) were amplified from the genomic DNA of 
patient CG-ASG-160. Similarly, CPAMD8 wild type and mutant genomic fragments 
encompassing exons 33-34 and the corresponding flanking sequences (final 173 bp of intron 
32 and initial 383 bp of intron 34) were obtained from the ASG-CG-30 proband. Detailed 
amplification protocols are provided in the Suppl. Methods. PCR products were cloned into 
the pTBN1 plasmid (a gift from Franco Pagani, Addgene plasmid #15125). Minigene DNA 
constructs were transfected into HEK-293T cells; the transcripts were analyzed by RT-PCR 
and direct Sanger sequencing. In vivo splicing of CPAMD8 was analysed using cDNA obtained 
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from one of the healthy controls described above. Detailed protocols are available in the 
Suppl. Methods. 
Western blotting and antibodies 
Samples used for Western blot analyses were fractionated by SDS-PAGE using the 
Mini-PROTEAN III Gel Electrophoresis System and transferred onto Hybond ECL 
nitrocellulose membranes (Amersham) for immunodetection as previously described 
(Aroca-Aguilar et al. 2013). CPAMD8 was detected using three commercial rabbit anti-
human CPAMD8 polyclonal primary antibodies (Ab 1: HPA031328, Ab 2: HPA031330, and 
Ab 3: HPA031327; Sigma), diluted to 1:100. Horseradish peroxidase-conjugated antibodies 
against rabbit IgG (#1858415, Pierce) were diluted to 1:1500. Chemiluminescence detection 
was performed as previously described (Aroca-Aguilar et al. 2013). 
Light and transmission electron microscopy (TEM) 
The trabeculectomy and zebrafish samples employed for light and TEM were fixed 
in 2.5% glutaraldehyde/4% paraformaldehyde, postfixed in 1% osmium tetroxide, and 
embedded in araldite. Semi-thin sections (0.5 μm) were stained with Toluidine blue and 
analyzed by light microscopy to select the best areas for TEM analysis or to study their 
histology. After uranyl acetate and lead citrate contrast, sections were photographed using 
a transmission-electron microscope (JEOL JEM 1010). Detailed protocols are available in the 
Suppl. Methods. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
Fluorescence immunohistochemistry (FIHC) 
Paraffin-embedded human eye sections (3 μm) and zebrafish embryo cryosections (10-14 
μm) were incubated with a rabbit anti-human CPAMD8 1:200 primary antibody 
(HPA031328, Sigma) and Cy2 donkey anti-rabbit 1:1000 secondary antibody (Jackson 
ImmunoResearch). Sections were also counterstained with DAPI and visualized using an 
LSM710 Zeiss confocal microscope. Fluorescence emitted by DAPI, the Cy2-conjugated 
antibody and embryo autofluorescence were registered at 411-464 nm, 490-518 nm and 
553-677 nm respectively. Detailed protocols are available in the Suppl. Methods.
Fluorescent whole mount immunohistochemistry (FWIHC) 
Ninety-six hpf phenylthiourea-treated and fixed embryos were incubated with a rabbit anti-
human CPAMD8 1:200 primary antibody (HPA031328, Sigma) and a Cy2 donkey anti-rabbit 
1:1500 secondary antibody (Jackson ImmunoResearch). Embryos were also counterstained 
with DAPI, mounted in low-melting agarose, and visualized in an LSM710 Zeiss confocal 
microscope. Fluorescence was detected as described earlier. Z-Stack maximum intensity 
projections of embryos were obtained with ZEN software (Zeiss). Detailed protocols are 
available in the Suppl. Methods. 
CRISPR/Cas 9 gene editing 
Deletions of approximately 100 bp were generated either in exon 4 or in exon 25 using the 
crRNAs pairs described in the Suppl. Methods. Cas9/tracrRNA/crRNA complex 
(approximately 3 nl) was injected into the animal pole of one-cell stage embryos (50-250 
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embryos/experiment) using a Femtojet 5247 microinjector (Eppendorf) under a Nikon DS-
Ri2 stereomicroscope. As a negative control, embryos were injected with Cas9/tracrRNA 
and no crRNA. For each crRNA pair and control, at least three independent experiments 
were performed using different zebrafish progenitors in each experiment. Detailed 
protocols are available in the Suppl. Methods. 
In silico analyses 
The different programs used to evaluate the deleterious effect of the different variants, to 
identify protein domains, and to align aa sequences are described in the Suppl. Methdos. 
Novel variants were named using directions from Mutalyzer (https://mutalyzer.nl/), 
according to reference sequences NM_015692.4 and NP_056507.3. 
Statistics 
Statistical comparisons between groups were performed using either the t-test or the one-
way ANOVA. Statistical significance of the difference in the proportion of rare SNVs between 
PCG patients and the gnomAD database was determined by the chi-square test. Statistical 
analysis of the data was performed using the SigmaStat 2.0 software (SPSS Science Inc.). 
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Results 
We investigated by next generation sequencing (NGS) the underlying genetic alterations in 
an atypical group of four glaucoma patients with variable ASD who, in addition, did not 
present with a family history of the disease. Gene variants were screened in three patients 
using an in-house developed gene panel comprising 82 genes related to ASD, glaucoma or 
ocular development. The fourth case was analyzed by trio whole-exome sequencing (WES). 
The variant filtering algorithm aimed to identify rare variants with potential recessive 
genotypes (i.e., a homozygous or compound heterozygous state) and predicted high 
functional impact (frameshift, non-sense, missense and donor/acceptor splicing sites). The 
filtering pipeline revealed biallelic CPAMD8 variants in the first three patients (CG-ASD-160, 
ASD-ANI-0066 and JG-ASD-33, Fig. 1A). CPAMD8 is a gene recently implicated in atypical 
autosomal recessive ASD (Cheong et al. 2016). One allele identified in patient CG-ASD-160 
was a single-nucleotide insertion (c.3686_3687insT) predicted to cause a frameshift and a 
premature termination codon (PTC) in the mutant protein (p.(Arg1231Profs*64)) and it was 
positioned within a conserved alpha-2 macroglobulin (A2M) thiolester-containing domain 
(Fig. 2). The second allele (c.1758+1_1758+4del) deleted the canonical GT dinucleotide 
required for normal splicing. It was predicted in silico to break the donor site (Table 1), 
potentially leading to the retention of intron 15 in the processed mRNA, as well as to a PCT 
at the fifth codon in the mutant open reading frame (ORF). The former variant has not been 
reported in the gnomAD database and the latter has a very low frequency (9.398e-5), with 
no homozygotes described (Table 1). Sanger sequencing confirmed the presence of these 
variants in the patient (Fig. S1) and in five family members, showing an inheritance pattern 
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compatible with recessive transmission (Fig. 1B). The filtering pipeline identified in the 
second patient (CG-ASD-ANI-0066) two close nucleotide substitutions: c.2063C>A and 
c.2070+4A>C (Fig. 1A). Visual inspection of aligned read sequences indicated that both
variants could be in the same chromosome. The former variant was predicted to result in 
the amino acid change p.(Ala688Asp) in the bait region domain of the protein (Fig. 2A), while 
the later affected the intron 17 donor splicing site (Fig. 2B). None of these variants have 
previously been reported in gnomAD. Bioinformatic pathogenic predictions classified the 
first variant as tolerated or probably damaging, whilst two different algorithms predicted 
the second one would break the intron 17 donor site (Table 1), potentially resulting in the 
retention of this intron in the mature mRNA with the subsequent creation of a new ORF 
that leads to creation of a PTC in the mutant mRNA (p.(Glu691Valfs*99)). Segregation 
analysis confirmed the presence in cis of both heterozygous nucleotide substitutions in the 
patient and in her mother, whereas the patient’s sister inherited the wild type allele (Fig. 
1B and Fig. S1). Further bioinformatic copy number variation (CNV) analysis using a 
bioinformatic read-depth approach revealed a putative exon-23 deletion, which was further 
validated by droplet digital PCR (ddPCR) (Fig. S3); to the best of our knowledge, it has not 
previously been reported. Segregation by ddPCR assay showed that the unaffected 
proband’s sister inherited the exon 23 deletion in the heterozygous state (Fig. S3). This 
variant was predicted to cause a frameshift at codon 979 introducing a PCT downstream 
from the deletion (p.(Ala979Argfs*49)). Although the father was not available for genetic 
studies, the absence of the CNV in the mother supports the notion that these variants were 
coinherited with the disease in a recessive fashion (Fig. 1B). The third patient (JG-ASD-33) 
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presented with two compound heterozygous CPAMD8 nucleotide substitutions (c.2807C>T 
and c.3991G>T) (Fig. 1A) that were inferred to cause missense variants (p.(Pro936Leu) and 
p.(Ala1331Ser), respectively). The former variant did not disrupt any of the A2M family 
domains, although it affected the amino acid residue Pro936 which shows high evolutionary 
conservation (Fig. S2), and the latter was positioned in the A2M thiolester-containing 
domain (Fig. 2A). The frequency of these variants was very low in gnomAD with no reported 
homozygous genotypes (Table 1). Prediction of pathogenicity with three programs showed 
discrepant results. p.(Ala1331Ser) was classified as probably damaging or damaging by two 
programs, while p.(Pro936Leu) was consider pathogenic by only one (Table 1). In addition, 
five algorithms contained in the Human Splicing Finder software indicated that variant 
p.(Ala1331Ser) had the potential to break an exonic splicing enhancer (ESE), resulting in a 
putative exon skipping with a likely associated severe functional disruption (Table 1). The 
presence of both variants and their segregation with the disease following a recessive 
pattern was confirmed by direct Sanger sequencing (Fig. 1B and Fig. S1). Trio WES in the 
fourth patient (CG-ASD-104) revealed potential pathogenic compound heterozygous 
variants only in CPAMD8 (Fig. 1A). The two variants identified in this gene consisted of a 
novel one-nucleotide deletion (c.2532del) (Table 1) inferred to result in a frameshift close 
to the C-terminal region of the A2M domain (p.(Lys845Argfs*14), Fig. 2A). The second 
alteration was a rare nucleotide substitution (c.2002C>T/rs200025505) with no reported 
homozygotes in gnomAD (Table 1) and predicted to result in a PCT (p.(Arg668*)) at the 
cleavage motif in the bait region (Fig. 2A). The two variants are predicted to be associated 
with a high functional impact because they would lead to NMD-dependent mRNA 
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degradation, resulting in LoF of the gene and the absence of CPAMD8 protein activity in the 
patient. The two variants were confirmed by Sanger sequencing (Fig. S1) and segregated 
with the disease according to a recessive inheritance (Fig. 1B). 
In light of the presence of CPAMD8 variants in CG-ASD patients we used the same gene 
panel and filtering algorithm to investigate the possible role of this gene in PCG. To that 
end, we selected 50 PCG patients from our previously reported cohort (Campos-Mollo et al. 
2009; López-Garrido et al. 2013). The selected subjects were negative for pathogenic 
genotypes in CYP1B1, FOXC1, FOXC2 or MYOC. Potential pathogenic CPAMD8 biallelic 
variants were identified only in patient PCG-30 (Fig. 3A). One allele, p.(Ala617Val), affected 
the A2M bait region domain (Fig. 2A) and the other one, c.4470+10_4470+11insT, flanked 
the donor splicing site of intron 34 (Fig. 2B). Both variants had very low frequencies with no 
reported homozygotes in gnomAD (Table 1). Two out of three bioinformatic tools classified 
p.(Ala617Val) as a moderate or probably damaging missense variant; in addition, this 
variant was predicted to break an ESE. Similarly, the intronic nucleotide insertion 
c.4470+10_4470+11insT also potentially affected intronic and/or ESEs (Table 1). The
variants were confirmed by Sanger sequencing (Fig. 3B and Fig. S1) but DNA samples from 
family members were not available for segregation analysis. In addition, we found that 
seven out of the 50 PCG patients (14%) carried seven different monoallelic rare CPAMD8 
nucleotide substitutions (Table S1), which were further confirmed by Sanger sequencing 
(Fig. S4). These variants are described in Suppl. Results. 
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Clinical features of patients with biallelic CPAMD8 variants 
The four CG-ASD patients who carried biallelic CPAMD8 variants presented variable anterior 
segment alterations. The mildest phenotype was observed in patient CG-ASG-160, who 
presented with subtle corectopia and iridocorneal adhesions (Fig. 4) along with very thick 
corneas and childhood-onset glaucoma (Table 2). This patient had normal zonulas in both 
eyes with no evidence of ectopia lentis. Case JG-ASD-33 was diagnosed with glaucoma in 
her teens in Romania, was subjected to trabeculectomy at the age of 31, developed 
malignant glaucoma in the RE before receiving treatment at San Carlos Clinical Hospital and 
currently suffers from terminal glaucoma in this eye. Eye examination revealed bilateral 
moderate corectopia with multiple iridocorneal adhesions (Fig. 4). In addition, this subject 
presented with posterior embryotoxon (Fig. 4) and a bilateral narrow anterior chamber with 
plateau iris configuration in the left eye (LE) and iatrogenic cataracts (Table 2). Anterior 
segment malformations present in patient CG-ASD-104 included bilateral corectopia, iris 
hypoplasia, posterior embryotoxon and iridocorneal adhesions (Fig. 4). Iris concavity, 
iridodonesis, megalocornea and a deep anterior chamber were additional clinical features 
of this case (Table 2). This patient had been diagnosed with bilateral congenital glaucoma 
at the age of 1, with IOP values before treatment of 20 and 40 mmHg in the RE and LE, 
respectively. In addition, she suffered from band keratopathy in the LE secondary to retinal 
detachment (Fig. 4). Case ASD-ANI-0066 presented with the most severe phenotype 
characterized by bilateral iris atrophy, coloboma, megalocornea, increased corneal 
thickness, bilateral cataracts and bilateral congenital glaucoma diagnosed at birth (Table 2). 
The four CG-ASD patients underwent different types of bilateral glaucoma surgery, which 
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included trabeculectomy, goniotomy and drainage valve implantation (Table 2). Patients JG-
ASD-33 and CG-ASD-ANI-0066 also require ocular drops for adequate IOP control (Table 2). 
The only PCG patient identified with biallelic CPAMD8 variants was diagnosed 1 week after 
birth with IOP values of 25 and 30 mmHg in the RE and LE, respectively, and with bilateral 
optic disc excavation of 0.4 (Table 2). Ocular exploration did not reveal any anterior segment 
abnormality and there were no signs of systemic alterations. This subject required bilateral 
goniotomy to control IOP. No additional lens or systemic alterations were detected in any 
of the five patients. 
Trabecular meshwork alterations associated with CPAMD8 LoF variants 
A trabeculectomy specimen from the RE of patient CG-ASD-104 was used for histological 
analysis. Light microscopy of semithin sections of the anterior chamber angle segment 
revealed the presence of SC and collector channels (CC) with open lumens and abnormal 
ciliary muscle (CM) insertion over a quite compact TM (Fig. 5A). Transmission electron 
microscopy showed the presence of apoptotic cells in the CM, characterized by cell 
shrinkage and nuclear condensation (Fig. 5B). Endothelial cells of both CC (Fig. 5C) and SC 
(Fig. 5D) showed vesicles and caveolae, supporting their functionality. The juxtacanalicular 
tissue (JCT) presented abundant "optically empty spaces", normal proportions of 
extracellular matrix components (collagen and elastic-like fibers) and apoptotic JCT cells 
(Fig. 5D). In the TM, most trabecular cells were absent and the few remaining showed clear 
signs of apoptosis, i.e., condensed chromatin that appears as dark areas in the nucleus of 
apoptotic cells (Fig. 5E and G, white arrowheads) and apoptotic bodies (Fig. 5E-I, white 
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arrows) which arise during the later phase of apoptosis and consist of cell fragments 
composed of intact cell membranes containing cytoplasm with tightly packed organelles 
with or without nuclear fragments (Elmore 2007). Remarkably, the corneoscleral TM (CTM) 
presented compact trabecular beams with variable thicknesses (Fig. 5E and F) and partially 
fused at some points (Fig. 5E and F). In addition, the trabecular beams core showed large 
deposits of coalescent and disorganized fibrillary collagen, abnormal deposits of basement 
membrane and irregularly distributed elastic-like fibers (Fig. 5E and F). The uveal TM (UTM) 
presented intertrabecular spaces (Fig. 5G) with partially fused trabecular beams (Fig. 5G). 
Trabecular beams core showed the accumulation of elastic-like fibers and densely packed 
and disorganized fibrillary collagen (Fig. 5G-I) arranged in onion-like layers (Fig. 5G), scarce 
non-fibrillar type VI collagen and thick basement membrane (Fig. 5H and I). 
Functional evaluation of the identified variants 
Fresh blood samples from family CG-ASD-104 were used to investigate the effect of the two 
identified variants on CPAMD8 mRNA levels by qRT-PCR. CPAMD8 transcript levels were 
reduced to approximately 30% of those observed in control subjects who did not carry any 
pathogenic variant in this gene (Fig. 6), demonstrating the functional disruption of CPAMD8 
in this patient. Unexpectedly, the mRNA levels in heterozygous carriers of the pathogenic 
variants were similar to those of controls, indicating the existence of the transcriptional 
adaptation or compensation of this gene to pathogenic mutations triggered by mRNA 
degradation (El-Brolosy et al. 2019). 
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Fresh blood samples were not available from families CG-ASD-160 and PCG-30. Therefore, 
we evaluated in vitro the splicing effect of variants predicted to affect intron processing 
using an assay based on a modified version of the α-globin-fibronectin EDB minigene 
(Cheong et al. 2016; Pagani et al. 2003). To that end, genomic DNA fragments containing 
these variants and their corresponding wild type alleles were cloned from the genomic DNA 
of patients (Fig. 7A and Fig. S5A) and expressed in HEK-293T cells as described in the 
Methods section. PCR analysis of minigene transcripts derived from patient CG-ASD-160 
(c.1758+1_1758+4del) using EDB specific primers p3/p4 showed a 482 bp band (Fig. 7B, 
band 1). By contrast, the wild type minigene version produced a 428 bp amplicon (Fig. 7B, 
band 2). Direct Sanger sequencing revealed that bands 1 and 2 corresponded to an aberrant 
splicing product that retained 54 nucleotides from intron 15 and to the normally spliced 
exon 15, respectively (Fig. 7B and Fig. S6A). This result indicates that elimination of the 
canonical splicing donor signal by variant c.1758+1_1758+4del leads to the activation of an 
intron 15 cryptic splicing donor site, resulting in the partial retention of intron 15 (Fig. 7B). 
Bioinformatic analysis confirmed the presence of a potential splicing donor signal at 
position +58 of the wild type intron (Fig. 7C). Therefore, partial retention of intron 15 
creates a new open reading frame with a PCT in the fifth codon (Fig. 7C, asterisk) that may 
finally lead to NMD-dependent mRNA degradation. Other minor amplicons were also 
observed in the mutant minigene assay, indicating the existence of other secondary 
uncharacterized transcripts (Fig. 7B). Approximately equal-intensity amplicons were 
obtained from control- and patient-derived minigenes, using vector-specific primers p1/p2, 
indicating no significant expression differences between the two DNA constructs (Fig. 7B, 
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band 3). Minigene analysis of the intronic variant identified in patient PCG-30 
(c.4470+10_4470+11insT) did not show any mRNA splicing effect under the experimental 
conditions used but did reveal a previously unidentified alternative transcript, which 
partially retained intron 34 and, thus, might be affected by the identified nucleotide 
insertion (Suppl. Results, S5A and B Fig. and Fig. S6A). The existence of this alternative 
transcript was demonstrated in peripheral human leukocytes of a control subject (Suppl. 
Results, Fig. S5C-E and Fig. S6C). Interestingly, these results show that the nucleotide 
insertion (c.4470+10_4470+11insT) becomes a coding variant (c.4480_4481InsT) in the 
alternative mRNA, resulting in frameshift and the premature translation termination of the 
new open reading frame (p.(Trp1494Leufs*5), Fig. S5E, blue asterisk). Thus, this variant will 
underlie specific NMD-dependent degradation of the new alternative transcript, supporting 
its pathogenicity. Further characterization of the alternative mRNA is required to 
completely understand the effect of this nucleotide insertion. 
No functional assays were available to evaluate the effect of the three missense variants 
identified in the study. 
Presence of CPAMD8 in adult human ocular tissues 
To the best of our knowledge the presence of CPAMD8 protein in adult human ocular tissues 
has not been studied. Western blot analysis of ocular fluids with three different commercial 
antibodies showed the presence of N- and C-terminal CPAMD8 fragments in aqueous 
humor (AH) and vitreous humor (Suppl. Results and Fig. S7). Next, we used one of these 
antibodies (Ab1) to study the distribution of this protein by confocal FIHC in adult human 
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ocular anterior segment tissues. CPAMD8 was detected in different epithelial and muscular 
tissues. In fact, we observed intense cytoplasmatic granular signals in the non-pigmented 
ciliary epithelium (NPCE) (Fig. 8A). Iris muscles (sphincter and dilator) (Fig. 8B) and especially 
longitudinal fibers of the CM (Fig. 8C) were also positively labeled. In addition, CPAMD8 was 
detected in the subcapsular lens epithelium, lens fibers (Fig. 8D), corneal epithelium, 
keratocytes and corneal endothelium (Fig. 8E, F and G, respectively). The specificity of these 
signals was supported by their absence in the corresponding negative controls (Fig. S8). 
Interestingly, the protein was not detected in the trabecular meshwork or SC (Fig. S9). 
Expression of cpamd8 in zebrafish ocular tissues 
To analyze the function of CPAMD8 in vivo and to evaluate its role in congenital glaucoma 
and ASD we used zebrafish as an animal model. DNA sequence homology analysis revealed 
a unique CPAMD8 zebrafish orthologue located on chromosome 22, with well-conserved 
intron-exon and protein domain organization (Fig. S10A and B, respectively). The two 
orthologue proteins also show a high amino acid sequence identity (65.5%). Ocular cpamd8 
expression was analyzed in zebrafish embryos by FWIHC using Ab1 at 96 hours post 
fertilization (hpf). The zebrafish epitope recognized by this antibody is 62% amino acid-
sequence-identical to the corresponding human epitope. Three-dimensional reconstruction 
by confocal laser scanning microscopy revealed specific periocular labeling, localized in the 
optic cup edge with superficial positive mesenchymal-like cells in the dorsoposterior 
quadrant of the eye and irregularly distributed in the periphery of the ocular globe (Fig. 9A). 
Observation of two representative confocal optical sections clearly showed cpamd8-
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positive cells irregularly located on the external edge of the optic cup and surrounding the 
ocular globe (Fig. 9B and C). The absence of green signals in the negative control supports 
the labeling specificity (Fig. S11). These results were confirmed by FIHC on frozen tissue 
sections, which also showed cpamd8 positive signals in the developing dorsal and ventral 
iridocorneal angles, in the iris, between the lens and the optic cup surface, and periocularly 
distributed around the ocular globe (Fig. S12, top panels), in positions that may correspond 
to periocular mesenchyme. Again, the absence of green labeling in the negative controls 
indicated the specificity of the detected signals (Fig. S12, bottom panels). 
F0 zebrafish phenotypes resulting from CRISPR/Cas9 cpamd8 inactivation 
To evaluate whether cpamd8 plays a role in early ocular development in zebrafish, we 
inactivated this gene using CRISPR/Cas9 genome editing. We generated two independent 
100 bp-deletions with crRNA pairs targeting exons 4 (cpamd8ex4) and 25 (cpamd8ex25) (Fig. 
S10A, crRNAE4a/crRNAE4b and crRNAE25a/crRNAE25b) as described in the Methods 
section. This approach has been demonstrated to be a rapid and efficient strategy for in 
vivo evaluation of LoF-associated phenotypes (Bhattacharya et al. 2015). The phenotypic 
evaluation was carried out using 50-200 F0 mosaic embryos in each experiment. At 96 hpf, 
approximately 1% of non-injected embryos died and only 3% of tracrRNA-injected embryos 
(negative control) showed lethal phenotypes characterized by generalized edema and 
aberrant morphology and they were classified as non-specific phenotypes (Fig. 10A). Lethal 
phenotypes increased to 15% and 6% in cpamd8ex4- and cpamd8ex25-targeted embryos, 
respectively. We observed a parallel decreased in normal phenotypes from 97% in control 
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embryos to 26% and 60% in cpamd8ex4- and cpamd8ex25-targeted embryos, respectively (Fig. 
10A). In addition, three similar abnormal phenotypes (Ph-1, Ph-2 and Ph-3, Fig. 10A) were 
present in cpamd8ex4- and cpamd8ex25-targeted embryos, which were classified according 
to the increasing degree of microphthalmia, pharyngeal maldevelopment, and pericardial, 
periocular and brain edema (Fig. 10B and C). The proportion of these phenotypes ranged 
from 14% to 25% in cpamd8ex4-targeted embryos and from 7% to 25 % in cpamd8ex25-
targeted embryos (Fig. 10A). Most of these embryos died at 7 dpf. These results indicate 
that the observed developmental alterations are not caused by off-target DNA cleavage. 
Moreover, these phenotypes were not observed in either tracrRNA-injected or uninjected 
embryos, indicating that they were specific. Immunohistochemical analysis of the three 
phenotypes revealed the progressive reduction of cpamd8 protein in periocular tissues, 
which correlated with the severity of ocular alterations, thereby supporting both correct 
cpamd8 inactivation and the specificity of the anti-CPAMD8 antibody (Fig. S13). Cpamd8 
mosaic disruption in the CRISPR/Cas9 injected embryos was confirmed by PCR analysis 
(Suppl. Results and Fig. S14). Next, we examined the structure of ocular tissues involved in 
glaucoma associated with phenotypes Ph-1 to Ph-3. Toluidine-blue-stained head sections 
of 96-hpf embryos confirmed progressive microphthalmia and showed increased spaces 
surrounding the brain and eyes filled with amorphous material, particularly in Ph-1 and Ph-
2 embryos, which indicates the existence of edema (Fig. 11K and M). Ph-2 and Ph-3 embryos 
were also characterized by pharyngeal cartilage underdevelopment (Fig. 11M and Q). 
Moreover, detailed observation of the anterior segment showed progressive iridocorneal 
dorsal and ventral angle hypoplasia (Fig. 11), with a decreased number of iris stroma cells, 
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i.e., iridophores, xantophores and mesenchymal cells (Fig. 11, “Dorsal Angle” and “Ventral
Angle” panels). Corneal epithelium cells presented increased size with apparent cell 
swelling from Ph-1 to Ph-3 (Fig. 11L, P and T). Transmission electron microscopy of dorsal 
and ventral iridocorneal angles demonstrated the presence of the primordial anterior 
chamber space in wild type and wild type-like embryos (Fig. 12B-C and G-H, respectively). 
Phenotypes Ph-1 to Ph-3 presented a reduction in this primordial space (in both the dorsal 
and ventral regions), which, in addition, was increasingly filled with cellular material, 
correlating with phenotype severity (Fig. 12L, M, Q, R, V and W). Irregular iridophore-
reflecting platelets correlated with the severity of the phenotype and were especially 
evident in phenotypes Ph-2 and Ph-3 (Fig. 12Q, V, R, and W). The two-cell-layer corneal 
epithelium was gradually thickened from phenotype Ph-1 to Ph3 (Fig. 12N, S and X). The 
most superficial corneal epithelial cell layer appeared edematous in phenotypes Ph-1 to 
Ph3, with swelling of intracellular organelles (Fig. 12N, S, and X, arrowhead), suggestive of 
apoptosis. The subepithelial cell layer showed an irregular contour (Fig. 12N, S, and X, cse). 
Thickening of the corneal stroma was evident, particularly in Ph-3 embryos (Fig. 12X and Y, 
cs). Collagen fibers in the corneal stroma of wild-type embryos were regularly arranged in 
regular 7-9 layers (Fig. 12E and J). By contrast, we observed abnormal ECM characterized 
by irregular collagen deposition with decreased fibril packing and the loss of collagen layers 
that also correlated with phenotype severity (Fig. 12O, T and Y). Finally, progressive thinning 
of the lens epithelium was also observed (Fig. 12I, N, S, and X). All these data indicate that 
cpamd8 disruption results in early anterior segment maldevelopment, which is 
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characterized mainly by dysgenesis of the iridocorneal angle, the presence of cellular 
material in the anterior chamber, and disrupted collagen deposition in the corneal stroma. 
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Discussion 
The primary purpose of this study was to identify by NGS the genetic alterations underlying 
CG-ASC in sporadic patients with no family history of the disease. This approach led to the 
identification of several potentially pathogenic CPAMD8 genotypes in four patients. This 
gene has recently been identified as playing a role in ASD8, an atypical form of ASD, clinically 
described in three families that, in addition to iris dysgenesis features such as bilateral iris 
hypoplasia, corectopia and ectropion uveae, also presented with bilateral lens alterations 
(i.e., ectopia lentis and cataracts) in the absence of glaucoma and inherited in a recessive 
fashion, in contrast to typical ASD, which is dominant (Alsaif et al. 2019; Cheong et al. 2016). 
Our patients also showed recessive inheritance of the disease, though they differ from 
those of the previous report in terms of the presence of glaucoma and the absence of 
ectopia lentis but cataracts that could be related to CPAMD8 dysfunction were present in 
one patient (CG-ASD-ANI-0066). Biallelic CPAMD8 variants have also been found in 
childhood and juvenile open-angle glaucoma patients (Siggs et al. 2020). Pathogenic 
CPAMD8 variants were also found in one PCG patient. In addition, the remarkably high 
frequency of monoallelic rare CPAMD8 variants (allele frequency <0.1%) in our PCG patients 
is significantly larger than the frequency of rare SNVs of this gene observed in the gnomAD 
database v2.1.1 (14% vs. 1.14%, p<0.0001) and suggests that they may play a role in non-
monogenic glaucoma, acting as modifier or susceptibility factors, although further studies 
are required to clarify the involvement of these variants in the disease. 
Our findings expand the spectrum of phenotypes associated with this gene, supporting that 
functional disruption of CPAMD8 underlies anterior segment alterations ranging from 
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isolated trabeculodysgenesis to varying degrees of iridocorneotrabeculodysgenesis with 
associated lens abnormalities in some cases. This phenotypic variability can be explained by 
different variables, including the effects of modifier genes, residual CPAMD8 protein 
activity, and environmental and/or stochastic factors, and possibly reflects the complexity 
of ocular development. The pathogenicity of the variants identified in this study is 
supported by their rarity in the general population and bioinformatic analysis, but further 
experimental studies are required to firmly establish the deleterious role of some of the 
missense variants. Interestingly, minigene analysis not only confirmed that one of the 
identified variants detected in patient CG-ASD-160 (c.1758+1_1758+4del) altered normal 
CPAMD8 splicing but also revealed an unexpected pathogenic mechanism for the intronic 
variant carried by patient PCG-30 (c.4470+10_4470+11insT), related to the identification of 
a previously uncharacterized alternative transcript. This alternative transcript retains the 
entire intron 33 and the proximal intron 34 flanking sequence. Intron retention is a 
mechanism of gene expression control in eukaryotes and is tightly regulated during 
differentiation and development (Vanichkina et al. 2018). The existence of this alternative 
mRNA implies that although the insertion of one nucleotide identified in patient PCG-30 
does not affect canonical splicing of intron 34, it initiates a frameshift and a PCT in the 
alternative transcript likely leading to its specific NMD-dependent degradation, with 
phenotypic manifestations restricted to those tissues in which the corresponding CPAMD8 
isoform is expressed. To date, three alternative CPAMD8 transcripts, translated into three 
different isoforms (CPAMD8-1a, CPAMD8-1b, and CPAMD8-2), have been described 
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(Cheong et al. 2016; Strausberg et al. 2002). Further studies are required to completely 
characterize this new identified transcript. 
In accordance with our previous studies, the finding of a large proportion (14%) of CG 
patients carrying infrequent heterozygous CPAMD8 variants also provides evidence for the 
role of CPAMD8 in non-monogenic or complex congenital glaucoma, reflecting the notions 
that it participates in the complex genetic regulation of ocular development, and that the 
combination of genetic defects in more than one of these genes may contribute to the 
abnormal development of the anterior segment of the eye (Ferre-Fernández et al. 2017; 
López-Garrido et al. 2013). 
Detailed histologic analysis of the anterior chamber angle of one of the patients (CG-ASD-
104) with LoF CPAMD8 variants revealed the presence of apparently normal SC and CC, but
the abnormal anterior CM insertion indicates an incomplete and arrested separation of 
some angle structures. In addition, the remarkable ECM alterations of the TM are an 
obvious explanation for the reduced AH outflow and IOP elevation in this patient, and 
support the notion that this gene plays a key role in ECM formation in the TM, and likely, in 
other tissues of the ocular anterior segment. CPAMD8 belongs to the A2M/C3 (alpha-2-
macroglobulin/complement 3) protein family (Li et al. 2004), which is composed of large 
multi-domain proteins with a broad spectrum of endopeptidase inhibitor activity (Rehman 
et al. 2013). Though the members of this family are evolutionarily distant, their overall 
architecture is highly conserved and plays multiple functions. A2M, the founding member 
of this family, is a soluble broad-spectrum proteinase inhibitor (Gonias 1992) that binds and 
regulates the biological activity of several hormones, cytokines and growth factors (Rehman 
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et al. 2013). Keeping in mind the structural relatedness of CPAMD8 and A2M proteins, we 
can speculate that CPAMD8 loss-of-function may result in the altered regulation of 
extracellular proteinases involved in ECM remodeling and/or in the defective regulation of 
its putative ligands, which might underlie the TM alterations observed in patient CG-ASD-
104. Further investigations are required to clarify the precise pathogenic mechanisms
underlying CPAMD8-associated phenotypes. 
Patients with CYP1B1-associated PCG show abnormal CM insertion and ECM alterations in 
the TM resembling those observed in this study (Garcia-Anton et al. 2017). Trabecular cell 
death was also a common feature in these two phenotypes, although it is produced by 
necrosis in CYP1B1-defective patients (Zhao et al. 2013) and by apoptosis in CPAMD8-
glaucoma. Endothelial trabecular cells maintain the balance between ECM components, 
such as collagen and elastic fibers (Polansky et al. 1984); therefore, their death may explain 
(at least in part) the ECM alterations observed in our patient. In addition, the CC and, in 
some cases the SC, were absent in CYP1B1-deficient patients. Although only one 
trabeculectomy specimen from patients with CPAMD8 LoF was available, these results 
indicate that CYP1B1 and CPAMD8 are involved in ECM deposition in the anterior segment 
and that their independent disruption results in isolated trabeculodysgenesis or broader 
anterior segment defects. 
We also analyze, for the first time, the expression of CPAMD8 in adult human ocular tissues 
and fluids by Western blot and immunohistochemistry. The presence of a predicted signal 
peptide in the polypeptide chain of CPAMD8 indicates that this is a secreted protein present 
extracellularly. In accordance with this idea, western immunoblot revealed proteolytic 
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fragments of this protein in both AH and vitreous humor. The electrophoretic size of these 
fragments (approximately 120 and 60-65 kDa) is consistent with a proteolytic processing of 
the protein in the RRRR furin cleavage site located at residues 668-671 (Fig. S8A), releasing 
two fragments with theoretical masses of approximately 133 kDa (N-terminal, 1215-aas) 
and 71 kDa (C-terminal, 642-aas). The difference between experimental and theoretical 
molecular masses may be due to posttranslational modifications such as glycosylation 
and/or to protein conformation. Consistent with this idea, the observed 120 kDa doublet 
may reflect differences in glycosylation of the C-terminal fragment. Interestingly, the full-
length protein (1885 aas and 206.7 kDa predicted molecular mass), was not identified in 
these fluids indicating that it was completely processed. In line with these results, CPAMD8 
fragments derived from posttranslational processing at the RRRR furin cleavage site have 
also been reported in U251 glioma cells (Li et al. 2004). Interestingly, most missense 
mutations detected in this study and in the previous study (Cheong et al. 2016) are located 
in the C-terminal fragment of the protein. Based on this data we can speculate that the C-
terminal portion of CPAMD8 plays a critical role in the function of the protein. Cleavage of 
other related proteins such as C3, C4, and C5, by a furin-type enzyme occurs intracellularly 
at the tetra-arginine linker site as part of the maturation process and results in two chains 
linked by disulfide bridges (Ricklin et al. 2016). Based on this data, we can propose that the 
proteolytic processing of CPAMD8 also occurs intracellularly in the secretory pathway, 
regulating its biological activity, though this hypothesis requires further experimental 
assessment. Previous proteomic studies have detected the presence of CPAMD8 protein in 
the human CB (Goel et al. 2013) and AH (Murthy et al. 2015), and transcriptomic analyses 
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have been identified CPAMD8 transcripts in the NPCE (Janssen et al. 2014). In addition, our 
results also demonstrate the intracellular presence of CPAMD8 protein in different 
epithelial (NPCE and corneal epithelium), endothelial (corneal endothelium), and muscular 
cells (ciliary and iris muscles), as well as in fibroblasts from the anterior segment of the eye. 
The presence of the signal peptide indicates that all these cells synthesize and secrete the 
protein to their surrounding extracellular medium. In fact, one of the most intense signals 
was observed in the NPCE, indicating that the protein detected in the AH is secreted, at 
least partially, by these cells. CPAMD8 was not seen in the adult human TM, which suggests 
that the protein secreted by the NPCE is transported by the AH to the iridocorneal angle 
and to other parts of the ocular anterior segment, where it may play a role in homeostasis 
and the remodeling of the ECM thanks to its putative activity as a proteinase inhibitor. These 
ideas are in accordance with our hypothesis of paracrine release of CB factors capable of 
affecting the physiology of the TM (Coca-Prados and Escribano 2007) as well as with the 
presence, in the AH, of other proteinase inhibitors, including A2M, secreted by the CB (Coca-
Prados et al. 1999; Escribano et al. 1995; Ortego et al. 1997). Altogether, these data indicate 
not only that CPAMD8 is required for normal anterior segment development but also that 
it may participate in the homeostasis of this part of the eye, supporting the notion that its 
functional disruption may underlie the different ASD phenotypes that this study describes. 
A previous report analyzed the spatiotemporal expression of CPAMD8 in the developing 
human eye (9-22 weeks of gestation) by RT-PCR and in situ hybridization, revealing, in 
accordance with our results, that it is expressed in the lens, iris, cornea and distal tips of the 
retinal neuroepithelium that form the iris and CB (Cheong et al. 2016). Similarly, CPAMD8 
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has been identified in the CB epithelium of healthy fetal and adult cattle (Hollmann et al. 
2017). 
To gain insight into the role of CPAMD8 in ocular anterior segment development, congenital 
glaucoma, and ASD, we analyzed the expression of the zebrafish orthologue, cpamd8, in the 
eyes of early embryos (96 hpf). The protein was detected in mesenchyme-like cells of the 
anterior segment, indicating that it may participate in the early morphogenesis of the iris, 
cornea and lens. CRISPR/Cas9 cpamd8 disruption revealed that F0 mosaic embryos 
presented remarkable iridocorneal angle hypoplasia, affecting mainly iris stroma cells, and 
a primordial anterior chamber filled with abnormal cellular material. Similar anterior 
chamber alterations have been described in pitx2-deficient zebrafish embryos (72 hpf), 
probably resulting from the presence of undifferentiated cells, cellular degradation, and/or 
sloughing and aberrant lipid or protein secretion (Hendee et al. 2018). These similarities 
suggest that pitx2 and cpmad8 might participate in related developmental pathways. 
Cpamd8-disrupted F0 embryos also replicated the corneal thickening observed in two 
patients (CG-ASD-160 and CG-ASD-ANI-0066). Interestingly, the abnormal collagen 
deposition observed in the corneal stroma suggests that cpamd8 is required for normal 
organization of the ECM structure and resembles collagen disorganization detected in the 
trabecular meshwork of one of the patients (CG-ASD-104). Moreover, the alteration of the 
lens epithelium in F0 embryos may correlate with cataracts developed by some ASD8 
patients. The phenotypic variability observed in the population of F0 embryos could result 
from different levels of residual cpamd8 activity, and the lethal phenotypes might be 
associated with a complete LoF of this gene. The establishment of a cpamd8 knockout 
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zebrafish line will be required for further cpamd8 functional characterization and to 
determine the role that this gene plays in glaucoma and ASD pathogenesis. Altogether, 
these results suggest that cpamd8 participates in ocular anterior segment development and 
in ECM organization, further supporting the notion that its functional disruption underlies 
a spectrum of CG and ASD phenotypes. 
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Figure titles and legends 
Fig. 1. Variant filtering scheme used for candidate variant identification and pedigree 
analysis of CPAMD8 variants in patients with congenital glaucoma and anterior segment 
dysgenesis. (A) Gene variants were identified by NGS using a gene panel comprising 121 
genes (CG-ASD-160, CG-ASD-ANI-0066 and JG-ASD-33) or by WES (CG-ASD-104) and filtered 
as indicated to identify candidate variants. (B) Candidate variant segregation. The black 
symbol indicates the presence of the disease. Arrows in the pedigrees show the index case. 
+ : wild-type allele. 
1
Frameshift, stop gained, start lost, splicing acceptor, and missense
variants. V1: p.(Arg1231Profs*64); V2: c.1758+1_1758+4del; V3: delex23; V4: 
p.(Ala688Asp)-c.2243+4A>C; V5: p.(Pro936Leu); V6: p.(Ala1331Ser); V7: p.(Lys845fs*13); 
V8: p.(Arg668*). 
Fig. 2. Localization of CPAMD8 variants identified in this study. (A) Scheme of the CPAMD8 
protein domain organization indicating the localization of coding variants (positions are 
referred to sequence NP_056507). Domains are indicated according to the Pfam database 
(https://pfam.xfam.org/). Ab1, Ab2, and Ab3: epitopes recognized by the three antibodies 
used in this study. Red triangle: position of the four Arg residues of the cleavage motif. A2M: 
Alpha-2-macroglobulin domain. A2M_BRD: Alpha-2-macroglobulin bait region domain. 
A2MR: Alpha-macroglobulin receptor binding domain. FA: Farnesoic acid 0-methyl 
transferase domain. MG2: Macroglobulin 2 domain of Alpha2-Macroglobulin. MG3: 
Macroglobulin 3 domain of Alpha2-Macroglobulin. MG4: Macroglobulin 4 domain of 
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Alpha2-Macroglobulin. L: low complexity Pfam domain. KAZ: Kazal-type serine protease 
inhibitor domain. SP: signal peptide. TED: A-macroglobulin thioester domain. (B) Genomic 
localization of CPAMD8 variants identified in this study. Positions correspond to reference 
sequence NM_015692. Red: missense variants. Green: synonymous variants. Black: intronic 
variants. 
Fig. 3. Variant filtering scheme used for candidate variant identification and pedigree 
analysis of CPAMD8 variants in a patient with primary congenital glaucoma. (A) Gene 
variants were identified by NGS using a gene panel comprising 121 genes and filtered as 
indicated in the left to identify candidate variants. (B) Pedigree of the family. The black 
symbol indicates the presence of the disease. The arrow in the pedigree shows the index 
case. +: wild-type allele. 
1
Frameshift, stop gained, start lost, splicing acceptor, and missense
variants. V9: p.(Ala617Val), V10: c.4470+10_4470+11insT. 
Fig. 4. Ocular phenotypes associated with CPAMD8 variants identified in patients with 
glaucoma and variable severity of bilateral anterior segment dysgenesis. Phenotype 
severity increases from patient CG-ASG-160 to CG-ASD-104. Patient CG-ASG-160 shows mild 
corectopia (white arrows) and iridocorneal adhesions visible under gonioscopy (white 
arrowheads). Iridectomies are present in the left eye (yellow arrows). Patient JG-ASD-33 
presents moderate corectopia (white arrows), iris hypoplasia, and posterior embryotoxon 
(black arrow), along with numerous irodocorneal sinequiae observed gonioscopically (white 
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arrowheads). Iridectomies were present in both eyes (yellow arrows). Patient CG-ASD-104 
showed one of the most severe phenotypes, characterized by corectopia (white arrows), 
evident iris hypoplasia, iridodonesis, and posterior embryotoxon (black arrow). Corneal 
calcification secondary to retinal detachment was present in the LE. Gonioscopy images 
were not available, but iridocorneal adhesions were also observed. LE: left eye. RE: right 
eye. 
Fig. 5. Anterior chamber angle dysgenesis in CPAMD8-associated CG. Trabeculectomy from 
the right eye of patient CG-ASD-104. (A) Light microscopy of the anterior chamber angle 
segment. Abnormal insertion of the CM; compact TM; open lumens of SC and CC. Squares: 
areas magnified in panels B, C, and D. (B-I) Transmission electron microscopy. (B) Aberrant 
CM position over the TM. Apoptotic CM cell (white arrowhead). (C) CC with open lumen and 
vacuoles in endothelial cells (black arrow). (D) Vacuoles (black arrow) and vesicles (black 
arrowhead) in an endothelial cell of the SC. JCT cells (J), elastic-like fibers (e), fibrillary 
collagen (c), optically empty spaces (*) and apoptotic bodies (white arrow) in the JCT. (E) 
CTM with apoptotic trabecular cells (white arrowheads) and apoptotic bodies (white arrow). 
Abundant fibrillary collagen (c) and elastic-like fibers (e). Intertrabecular spaces (black 
double arrow) alternate with fused trabecular beams (black arrowhead). (F) Trabecular 
beams filled with densely packed and disorganized fibrillary collagen (c), elastic-like fibers 
(e) and thick basement membrane (bm). Trabecular beams (white double arrow) present
variable thickness and partial fusions (black arrowhead). (G) UTM with intertrabecular 
spaces (white double arrow), fused trabecular beams (black arrowhead), apoptotic 
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trabecular cells (white arrowhead) and apoptotic bodies (white arrow). In cross-sectioned 
trabecular beams (inset in G) elastic material (e) and fibrillary collagen (c) are arranged in 
onion-like layers. (H and I) UTM trabecular beam with apoptotic cell debris (white arrow), 
abundant densely packed and disorganized fibrillary collagen (c), thickened basement 
membrane (bm), scarce collagen VI (CVI), and elastic-like fibers (e). CC: collector channel. 
CM: ciliary muscle. CTM: corneoscleral trabecular meshwork. EC: endothelial cell. JCT: 
juxtacanalicular tissue. SC: Schlemm's canal. TM: trabecular meshwork. UTM: uveal 
trabecular meshwork. Scale bars: 50 μm in A; 5 μm in B and G; 2 μm in C and E; 1 μm in D, F 
and inset in G; 0.2 μm in H and 0.5 μm in I. 
Fig. 6. Reduced CPAMD8 mRNA levels in the CG-ASD-104 patient. The mRNA levels were 
measured by qRT-PCR using RNA purified from peripheral blood leukocytes as described in 
the Methods section. The results are expressed as a relative expression to control 1 (normal 
subject with no pathogenic CPAMD8 variants). Controls 1 and 2 are unrelated healthy 
subjects. +: wild-type allele. V7: p.(Lys845fs*13). V8: p.(Arg668*). Asterisks indicate 
statistical significance compared to the control: p < 0.001 (***). Statistical significance was 
calculated by ANOVA. 
Fig. 7. Functional analysis of the c.1758+1_1758+4del CPAMD8 variant identified in patient 
CG-ASD-160. (A) Scheme of the cDNA construct used for in vitro mRNA splicing assay using 
the pTBN1 vector (blue region). Wild type and mutant (c.1758+1_1758+4del) CPAMD8 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
46 
genomic fragments are indicated in yellow. Vertical black arrows: restriction endonuclease 
sites used for cloning. (B) Agarose electrophoresis analysis of wild type (WT) and mutant 
(MUT) transcripts generated by RT-PCR using primers p3-p4 (left panel). Transfection 
efficiency was assessed by PCR amplification using minigene vector primers p1-p2 (band 3). 
The different amplicons were analysed by Sanger sequencing (Fig. S6A) and the inferred 
organization is shown on the right. (C) Prediction of a potential splicing donor signal (GTGC) 
by the Human Splicing Finder (HSF) software. HSF scores for wild type and mutant alleles 
are indicated in green and red, respectively. Note that HSF values for the canonical and 
alternative splicing sites are similar (78 and 75, respectively). Strong sites present values 
higher than 80. Green arrowhead: canonical splicing cleavage site. Red arrowhead: position 
of the c.1758+1_1758+4del variant. Red asterisk: position of a PCT in the fifth codon of the 
mutant reading frame. Nucleotides of the canonical splicing signal (GTAG), which are 
deleted in the mutant allele, are indicated. 
Fig. 8. Localization of CPAMD8 protein in adult human ocular anterior segment tissues. For 
fluorescent immunohistochemistry, histological sections (3 µm) were incubated with either 
a rabbit anti-human CPAMD8 primary antibody (HPA031328; Sigma) and a Cy2-conjugate 
donkey anti-rabbit secondary antibody (green signal) (1:200) (A–G) or with only a secondary 
antibody as a negative control (1:1000) (Fig. S8). Confocal wide-field micrographs of ciliary 
processes (A), iris (B), pars plana/ciliary muscle (C), lens epithelium (D), detailed images of 
the corneal epithelium (E), corneal stroma and keratocytes (F), and corneal endothelium 
(G). Scale bars correspond to 50 μm in panels A, D, E, F, G, and to 100 μm in panels B and C. 
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Red signals correspond to tissue autofluorescence. BM: Bowman’s membrane. CEN: corneal 
endothelium. CEP: corneal epithelium. CM: ciliary muscle. CS: corneal stroma. DM: 
Descemet’s membrane. IDM: iris dilator muscle. IPE: iris pigment epithelium. IS: iris stroma. 
ISM: iris sphincter muscle. K: keratocyte. LC: lens capsule. LCM: longitudinal fibers of the 
ciliary muscle. LF: lens fibers. NPCE: non-pigmented epithelium. PCE: pigmented epithelium. 
S: stroma. SCLE: subcapsular lens epithelium. 
Fig. 9. Fluorescent whole-mount immunohistochemical detection of cpamd8 in the 
embryonic zebrafish eye (96hpf). The embryos were incubated with either rabbit anti-
human CPAMD8 primary antibody (HPA031328; Sigma) (1:200) and Cy2-conjugated donkey 
anti-rabbit secondary antibody (1:1500) (A-C) or only a secondary antibody as a negative 
control (D-F). (A) Three-dimensional reconstruction from z-stack scanned confocal 
microscopy images (144 μm) of the eye. (B and C) Optical sections 2 and 9, from the exterior 
ocular surface, were selected from z-stack images to show the precise localization of the 
green signal between the optic cup surface and lens (arrow) and in the periocular 
mesenchyme surrounding the ocular globe (arrowhead). Red: tissue autofluorescence. 
Discontinuous line: Cpamd8 positive signals in the dorsoposterior quadrant of the eye. The 
cross indicates the position of the embryonic axes (D: dorsal; P: posterior; V: ventral; A: 
anterior). The image is representative of the result observed in 10 embryos. INL: inner 
nuclear layer; IPL: inner plexiform layer; L: lens; ONL: outer nuclear layer; OPL: outer 
plexiform layer; R: retina. 
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Fig. 10. Analysis of F0 zebrafish phenotypes resulting from CRISPR/Cas9 cpamd8 
inactivation (96-hpf). Zebrafish embryos were microinjected with CRISPR/Cas9 
ribonucleoprotein complexes targeting cpamd8 exon 4 (cpamd8ex4) or exon 25 (cpamd8ex25). 
Embryos microinjected with Cas9/tracrRNA ribonucleoprotein complexes and no crRNA 
were used as controls (tracrRNA). Untreated wild type embryos were also used as an 
additional control (WT). Treated embryos (F0) were classified into four phenotypes (WT-like, 
Ph-1, Ph-2, and Ph-3) according to increasing severity. (A) Proportion of F0 zebrafish 
phenotypes. Values correspond to the mean +-SEM of triplicate experiments with 50 to 250 
embryos per experiment. Phenotypes resulting from targeting of cpamd8 exon 4 (B) or exon 
25 (C). Lateral and ventral brightfield micrographs show similar abnormal phenotypes 
resulting from the targeting of the two exons, including microphthalmia (blue arrowheads), 
jaw maldevelopment (red arrowheads), and pericardial and periocular edemas (black and 
white arrowheads, respectively). Scale bars represent 200 m. 
Fig. 11. Histological analysis of F0 zebrafish phenotypes resulting from CRISPR/Cas9 
cpamd8 inactivation (96-hpf). (A, E, I, M and Q) Semi-thin (500 nm) transverse head 
sections were stained with Toluidine blue. WT: wild type. WT-L: wild type-like. Ph-1: 
phenotype 1. Ph2: phenotype 2. Ph3: phenotype 3. Progressive microphthalmia and 
enlarged intracranial and periocular spaces filled with amorphous material (black arrows), 
correlate with the severity of phenotypes. Underdevelopment of pharyngeal cartilages, 
ceratohyal (arrowhead), and the palatoquadrate (red arrows) are also present in phenotypes 
Ph-2 and Ph-3. Scale bar: 100 µm. The squares and rectangles indicate the areas of the 
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images magnified in the indicated panels. (B and C) The development of wild type 
iridocorneal dorsal and ventral angles shows normal pigment cell stratification in the iris 
with xantophores and idridophores in the stroma. (D) The cornea epithelium, 
subepithelium, stroma, and endothelium in contact with the anterior lens epithelium are 
observed in wild type embryos. Progressive anterior angle chamber reduction and 
hypoplasia of dorsal (F, J, N and R) and ventral (G, K, O, and S) iris stroma, affecting 
iridophores and xantophores, correlates with increasing phenotype severity (Ph-1 to Ph-3). 
(H, L, P, and T). Corneal epithelial swelling and stroma thickening increase with phenotype 
severity (Ph-1 to Ph-3). Ir: iridophores. xa: xantophores. ipe: iris pigmented epithelium. ac: 
anterior chamber. c: cornea. ce: corneal epithelium. cse: corneal subepithelium. cs: corneal 
stroma. cn: corneal endothelium. le: lens. Scale bar in “Eye” panels: 50 μm. Scale bar in 
“Dorsal Angle” and “Ventral Angle” panels: 4 μm. Scale bar in “Cornea” panels: 5 μm. 
Histological analysis of the negative control (Cas9/tracrRNA ribonuclease complex and no 
gRNA) is available in Fig. S15. 
Fig. 12. Electron microscopy of F0 zebrafish ocular anterior segment phenotypes resulting 
from CRISPR/Cas9 cpamd8 inactivation (96-hpf). Thin tissue sections were processed as 
described in the Methods section. (A, F, K, P, and U) Toluidne-blue-stained histological eye 
sections from Fig. 11 are used as a reference to indicate the position of the electron 
micrographs. The squares in the “Eye” and “Cornea” panels indicate the areas of the images 
magnified in the indicated panels. (B and C) Wild type dorsal and ventral iridocorneal angles, 
respectively, showing the early formation of the anterior chamber space and iris structures. 
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(D and E) Wild type cornea and corneal stroma, respectively. Note the dense, regularly 
packed collagen fibrils in the stroma running parallel to each other and that are stacked, 
forming layers or lamellae. No alterations were observed in the iridocorneal angle (G and H) 
or in the cornea (I and J) of wild type-like phenotypes. (L, Q, and V) The primordial dorsal 
anterior chamber is progressively filled with cellular material, which correlates with 
phenotype severity from Ph-1 to Ph-3. (M, R and W) A similar alteration is present in the 
primordial ventral anterior chamber. (N, S, and X) Increasing cytoplasm and organelle 
swelling (black arrowhead) in the corneal epithelium, suggestive of necrosis. (E, J, O, T, and 
Y) Progressive collagen disorganization in the corneal stoma correlating with genotype
severity, and characterized by decreased packing and irregular deposition of collagen fibrils 
with loss of collagen lamellae. Squares in different panels indicate enlarged areas. Ir: 
iridophores. xa: xantophores. ipe: iris pigmented epithelium. ac: anterior chamber. c: 
cornea. ce: corneal epithelium. cse: corneal subepithelium. cs: corneal stroma. cn: corneal 
endothelium. le: lens epithelium. Scale bars represent 50 μm in the “Eye” panels, 4 μm in 
the dorsal angle, ventral angle and cornea photographs; and 0.2 μm in the “stroma” panels. 
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Table 1. Biallelic CPAMD8 variants identified in patients diagnosed with CG-ASD or PCG. 
Family Chromosome position 
(hgv37) 
cDNA 
(NM_015692.4) 
Protein (NP_056507.3) Allele 
frequency/numb
er of 
homozygotes 
(gnomAD) 
aSIFT/bPolyphen/c
EVEP/dDANN 
eHSF 3.0 
predicted 
effects (# of 
algorithms) 
Reference 
number 
CG-ASG-160 19:17025566 
19:17088173 
c.3686_3687insT
c.1758+1_1758+4d
el
p.(Arg1231Profs*64) 
fp.(Val587Serfs*5) 
0 (0) 
9.398e-5 (0) 
-/-/-/- 
-/-/-/- 
- 
DSB (2) 
ss3943621968 
rs577740063 
CG-ASG-ANI-
0066 
19:17085914 
19:17085903 
19:17049179-17049281 
c.2063C>A
c.2070+4A>C
del ex23
p.Ala688Asp
fp.(Glu691Valfs*99)
p.(Ala979Argfs*49)
0 (0) 
0 (0) 
0 (0) 
T (0.33)/PD (1)/-/- 
-/-/-/- 
- 
DSB (2) 
- 
ss3943621972 
ss3943621971 
J-ASD-33 19:17017798 
19:17049243 
c.3991G>T
c.2807C>T
p.(Ala1331Ser) 
p.(Pro936Leu) 
7.657e-5 (0) 
0.0008707 (0) 
T (0.12)/PD 
(0.624)/M/0.983 
T (0.1)/B 
(0.17)/M/0.979 
CSSA (1), ESEB 
(5) 
No effect 
rs754711230 
rs200400599 
CG-ASG-104 19:17058014 
19:17085975 
c.2532del
c.2002C>T
p.(Lys845Argfs*14) 
p.(Arg668*) 
4.02071e-06 (0) 
5.481e-5 (0) 
-/-/-/- 
-/-/-/- 
- 
- 
ss3943621970 
rs200025505 
PCG-30 19:17086870 
19:17014360 
c.1850C>T
c.4470+10_4470+1
1insT
p.(Ala617Val) 
gp.(Trp1494Leufs*5) 
1.635e-5 (0) 
2.031e-5 (0) 
T (0.06)/PD 
(0.686)/M/- 
-/-/MF/- 
ESEB 
ISEB (3), ESEC 
(3) 
rs549230080 
rs754569481 
CSSA: Cryptic Splicing Site Activated. DSB: Donor Site Broken. ESEB: Exonic Splicing Enhancer Broken. ESEC: Exonic Splicing Enhancer Created. ISEB: Intronic Splicing Enhancer 
Broken. -: not apply. aThreshold for SIFT intolerance is 0.05. bPolyphen scores: 0.0-0.15, benign; 0.15-1.0, possibly damaging; 0.85-1.0, damaging. cEVEP: Ensembl Variant 
Effect Predictor: L, low; M, moderate; MF: modifier. dDeleterious annotation of genetic variants using neural networks (DANN) score: 0-1, 1 is given to the variants predicted 
to be the most damaging.; B, benign; D, damaging; PD probably damaging; T, tolerated. eHSF: Human Splicing Finder software (http://www.umd.be/HSF3). fFrameshift 
predicted in the open reading frame (ORF) originated by retention of the corresponding intron. gFrameshift predicted in the ORF of the new alternative transcript identified 
in this study, which retains the proximal intron 34. 
Table 1
Table 2. Ophthalmological features of patients with biallelic CPAMD8 variants. 
Patient CG-ASD-160 CG-ASD-ANI-0066 JG-ASD-33 CG-ASD-104 PCG-30 
Age at diagnosis/age at last 
ophthalmic revision 
Infantile/36 y Birth/35 y Juvenile/25 y Birth/17 y 1 w/8 y 
Inheritance AR AR AR AR AR (putative) 
BCVA (RE/LE) 0.25/1 0.5/0.5 0.66/1 0.2/LP 0.7/0.5 
Refraction (RE/LE) -12.00/-9.00 -4.25/-4.0 -3.50/+1.50 -6.00/-18.00a NA 
Axial length (mm) (RE/LE) 29.38/26.69 ND 22.67/22.23 26.16/36.79 NA 
AC depth (mm) (RE/LE) 4.16/4.59 NA Narrow/Narrow 5.03/3.26 NA 
Lens thickness (RE/LE) (mm) 5.13/4.87 
(Clear lens) 
NA (B) (CS) 5.13/4.87, iatrogenic 
cataract (B) 
Clear lens/Aphakic NA 
Iris Mild C Coloboma and AS 
(B) 
Moderate C and AS 
(B), PI (B) 
AS, C, ID, IH and 
IC (B) 
Normal 
Central corneal thickness (m) 
(RE/LE) 
665/640 600/600 539/559 NA NA 
Corneal morphology Normal MC (B) PE (B) MC and PE (B) Normal 
Posterior segment Coroidosis, 
miopía 
Normal Normal 
Glaucoma + (B) + (B) + (B) + (B) + (B)
IOP at diagnosis (mm Hg) 
(RE/LE) 
NA NA NA 20/40 25/30 
Last IOP (mm Hg) (RE/LE) 20/18 18/18 20/20 16/16 NA 
C/D ratio at diagnosis (RE/LE) 0.8/0.8 NA NA 0.6/0.6 0.4/0.4 
Last cup/disc ratio (RE/LE) 0.8/0.8 NA 0.9-0.3 0.6/0.9 NA 
Glaucoma surgery (number, 
laterality) 
G (1, B), T (1 
RE/2 LE) 
G (1, B), Cs (1, B) T (1, B) G (3, B); T (1, B); 
AV (1, LE); V (B) 
G (1, B) 
Number of antiglaucoma 
drugs (RE/LE) 
1/1 2/2 0/4 0/0 NA 
aBefore vitrectomy. AC: anterior chamber; AV: Ahmed valve; AS: anterior synequia; B: bilateral; BCVA: best corrected visual acuity; C: corectopia; C/D: cup/disc; 
CS: cataract surgery; G: goniotomy; ID: iridodonesis; IH: iris hypoplasia; IC: iris concavity; IOP: intraocular pressure; LP: light perception; MC: megalocornea; 
NA: no available; NE: no evaluable; PE: posterior embryotoxon; PI: plateau iris; RE: right eye; LE: left eye; T: trabeculectomy; V: vitrectomy; y: year; w: week. 
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